Neutrophil elastase inhibitor, sivelestat, attenuates acute lung injury after cardiopulmonary bypass in the rabbit endotoxemia model

Ann Thorac Surg. 2007 Jan;83(1):153-60. doi: 10.1016/j.athoracsur.2006.08.023.

Abstract

Background: Neutrophil elastase probably contributes to the development of acute lung injury after cardiopulmonary bypass (CPB) in patients with infection or shock. We evaluated whether pretreatment with sivelestat sodium hydrate, a neutrophil elastase inhibitor (EI), can prevent acute lung injury caused by CPB.

Methods: Rabbits were assigned four groups: CPB for 60 minutes, control CPB group; low-dose lipopolysaccharide (LPS) administration without CPB, LPS group; CPB after lipopolysaccharide administration, LPS+CPB group; or preparation with continuous infusion of sivelestat and CPBs after lipopolysaccharide administration, EI group. Blood samples to determine blood gas concentration, plasma elastase activity, and plasma interleukin-8 levels were obtained. Histopathologic examinations of the lung were performed.

Results: The decreased arterial oxygen pressure at the end of CPB was observed in the LPS+CPB group only, but was suppressed in the EI group (p < 0.01). Elastase activity was markedly elevated at 120 minutes after CPB, and interleukin-8 levels were markedly elevated at 180 minutes in the LPS+CPB group but were much lower (p < 0.05) in the EI group. Histopathology demonstrated accumulation of polymorphonuclear neutrophils in bronchoalveolar areas in the LPS+CPB group (p < 0.01). Pulmonary myeloperoxidase activity was significantly lower in the LPS+CPB group than in the other groups (p < 0.01). These changes were minimal in the EI group.

Conclusions: The combination of low dose LPS+60 minutes of CPB, but neither intervention alone, produced evidence of acute lung injury in a rabbit model. This did not occur when the animals were pretreated with sivelestat.

MeSH terms

  • Animals
  • Cardiopulmonary Bypass / adverse effects*
  • Glycine / analogs & derivatives*
  • Glycine / therapeutic use
  • Interleukin-8 / blood
  • Leukocyte Elastase / antagonists & inhibitors*
  • Leukocyte Elastase / physiology
  • Lipopolysaccharides / toxicity*
  • Neutrophils / physiology
  • Peroxidase / metabolism
  • Rabbits
  • Respiratory Distress Syndrome / prevention & control*
  • Sulfonamides / therapeutic use*

Substances

  • Interleukin-8
  • Lipopolysaccharides
  • Sulfonamides
  • sivelestat
  • Peroxidase
  • Leukocyte Elastase
  • Glycine